Some Good News on Drug Pricing, More to Be Done
August 20, 2026
Last week’s Consumer Price Index release from the U.S. Bureau of Labor Statistics included some good news on prescription drug
Join Us Live for a Discussion on Medicare, Democracy, and the Future of Health Care
Prescription Drugs
The Inflation Reduction Act (IRA) takes important steps to reduce drug prices and lower costs for people with Medicare and the program, such as capping beneficiary out-of-pocket spending; requiring Medicare to negotiate drug prices; and expanding eligibility for the full Part D low-income subsidy (LIS). We support an implementation process that centers the beneficiary experience and look forward to building upon these landmark policies.
Administration to Pull Back on Premium Help for Part D Beneficiaries
July 30, 2026
On Tuesday, the Trump administration announced that it would end the Part D Premium Stabilization Demonstration at the end of
Priority Issues Across Medicare, Part 2: Private Plans and Information Needs
June 25, 2026
The Medicare Rights Center’s work touches all aspects of the Medicare program, including Original Medicare (OM), private Medicare Advantage (MA)
GLP-1 Weight-Loss Drug Demonstration Begins July 2026
June 4, 2026
Starting in July 2026, some people with Medicare will be eligible for Medicare coverage of certain weight-loss medications through the
Supreme Court Declines to Hear Medicare Drug Price Negotiation Challenge
May 21, 2026
This week, the Supreme Court rejected appeals from pharmaceutical companies challenging the Medicare drug price negotiation program established by the
New Study Underscores IRA’s Successes, Opportunities for Future Reforms
April 23, 2026
A recent JAMA article found two key Inflation Reduction Act (IRA) prescription drug provisions that took effect in 2024—the elimination
What the Inflation Reduction Act Means for Older Adults and People With Disabilities
April 8, 2026
The Inflation Reduction Act (IRA) of 2022 made key changes in Medicare law and coverage to improve prescription drug affordability for older adults and people with disabilities. Since its passage, however, some stakeholders and lawmakers have targeted IRA policies for revision or repeal, especially the law’s Medicare Drug Price Negotiation Program.
IRA Leading to Better Medicare Coverage of Negotiated Drugs
March 5, 2026
A new analysis from KFF shows that the Inflation Reduction Act (IRA) has helped Medicare Part D enrollees gain access
Proposed Part D Payment Model Falls Short
February 26, 2026
This week, the Medicare Rights Center commented on a proposal from the Centers for Medicare and Medicaid Services (CMS) to
Comments on Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model
February 23, 2026
The Medicare Rights Center submitted these comments in opposition to the GUARD model for raising beneficiary drug costs.
Some Good News on Drug Pricing, More to Be Done
August 20, 2026
Last week’s Consumer Price Index release from the U.S. Bureau of Labor Statistics included some good news on prescription drug
Administration to Pull Back on Premium Help for Part D Beneficiaries
July 30, 2026
On Tuesday, the Trump administration announced that it would end the Part D Premium Stabilization Demonstration at the end of
Priority Issues Across Medicare, Part 2: Private Plans and Information Needs
June 25, 2026
The Medicare Rights Center’s work touches all aspects of the Medicare program, including Original Medicare (OM), private Medicare Advantage (MA)
GLP-1 Weight-Loss Drug Demonstration Begins July 2026
June 4, 2026
Starting in July 2026, some people with Medicare will be eligible for Medicare coverage of certain weight-loss medications through the
Supreme Court Declines to Hear Medicare Drug Price Negotiation Challenge
May 21, 2026
This week, the Supreme Court rejected appeals from pharmaceutical companies challenging the Medicare drug price negotiation program established by the
New Study Underscores IRA’s Successes, Opportunities for Future Reforms
April 23, 2026
A recent JAMA article found two key Inflation Reduction Act (IRA) prescription drug provisions that took effect in 2024—the elimination
What the Inflation Reduction Act Means for Older Adults and People With Disabilities
April 8, 2026
The Inflation Reduction Act (IRA) of 2022 made key changes in Medicare law and coverage to improve prescription drug affordability for older adults and people with disabilities. Since its passage, however, some stakeholders and lawmakers have targeted IRA policies for revision or repeal, especially the law’s Medicare Drug Price Negotiation Program.
IRA Leading to Better Medicare Coverage of Negotiated Drugs
March 5, 2026
A new analysis from KFF shows that the Inflation Reduction Act (IRA) has helped Medicare Part D enrollees gain access
Proposed Part D Payment Model Falls Short
February 26, 2026
This week, the Medicare Rights Center commented on a proposal from the Centers for Medicare and Medicaid Services (CMS) to
Comments on Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model
February 23, 2026
The Medicare Rights Center submitted these comments in opposition to the GUARD model for raising beneficiary drug costs.